ETF veteran Kevin Kelly is the force behind Kelly ETFs, which this month introduced three funds with distinctly different focuses.
JNJ has been in a longer-term uptrend but that may not be enough to keep the rally going.
Let's take a look at the charts and indicators.
This health biotech has been dealt some tough hands, but is still at the table. Here's my take.
Here's where aggressive traders could go long BMRN.
The shares of the animal health company could be finding a bottom after losing substantial ground since the start of the year.
The firm certainly seems to have the wind at its sails right now.
Here's where traders could go long.
The biotech sector looks ripe for staging a comeback, but a significant geopolitical event could throw the entire market for a loop.
After a huge drop in recent weeks, these shares look oversold -- and an insider seems to agree.